Inactive Instrument

Aceragen, Inc. Nyse

ACGN

US00445F1093

Biotechnology & Medical Research

Idera Pharmaceuticals, Inc. will Change its Name to Aceragen, Inc

January 17, 2023 at 09:59 pm

Effective January 17, 2023, Idera Pharmaceuticals, Inc. will change its name to Aceragen, Inc.

Latest news about Aceragen, Inc.

Aceragen Inc is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Companyâs pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
CELLTRION, INC.	-13.50%	26.03B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	10.64B

Other Biotechnology & Medical Research

Aceragen, Inc. Nyse

Equities

ACGN

US00445F1093

Biotechnology & Medical Research

Idera Pharmaceuticals, Inc. will Change its Name to Aceragen, Inc

Latest news about Aceragen, Inc.

Chart Aceragen, Inc.

Company Profile

Sector Other Biotechnology & Medical Research